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Abstract In this paper we examined whether stem cells and
factors responsible for their movement may serve as new bi-
ological markers of anxiety disorders. The study was carried
out on a group of 30 patients diagnosed with panic disorder
(examined before and after treatment), compared to 30 healthy
individuals forming the control group.We examined the num-
ber of circulating HSCs (hematopoetic stem cells) (Lin
−/CD45 +/CD34 +) and HSCs (Lin−/CD45 +/AC133 +), the
number of circulating VSELs (very small embryonic-like
stem cells) (Lin−/CD45−/CD34 +) and VSELs (Lin−/CD45
−/AC133 +), as well as the concentration of complement com-
ponents: C3a, C5a and C5b-9, SDF-1 (stromal derived factor)
and S1P (sphingosine-1-phosphate). Significantly lower
levels of HSCs (Lin−/CD45 +/AC133 +) have been demon-
strated in the patient group compared to the control group both
before and after treatment. The level of VSELs (Lin−/CD45
−/CD133 +) was significantly lower in the patient group be-
fore treatment as compared to the patient group after
treatment.
The levels of factors responsible for stem cell movement
were significantly lower in the patient group compared to the
control group before and after treatment. It was concluded that
the study of stem cells and factors associated with their move-
ment can be useful in the diagnostics of panic disorder, as well
as differentiating between psychotic and anxiety disorders.
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Introduction
According to the current version of the International Statistical
Classification of Diseases and Related Health Problems (ICD-
10), panic disorder may be diagnosed in a situation of occur-
rence of a few severe anxiety attacks with concurrent auto-
nomic symptoms within the period of one month. Panic at-
tacks are unrelated to a real situation of threat, they appear
unrelated to a known or predicted situation, between attacks
one is relatively free from symptoms of anxiety [1]. In re-
search by Grant et al., lifetime prevalence of panic disorder
(PD) is 5.1 %, in the case of PD without agoraphobia 4.0 %
and in panic disorder with agoraphobia 1.1 % [2]. The etiolo-
gy of anxiety disorders is not clear, it is believed that both
environmental and genetic factors are responsible for their
occurrence. In their meta-analysis, Hettema et al. estimated
the heritability of PD at 0.48 (95 % CI:. 41–54) ‘[3]. For both
panic disorder and generalized anxiety disorder the MZ: DZ
concordance ratio was more than 2:1 [4], Mendlewicz et al.
showed a significantly higher risk of developing PD among
relatives of patients with PD [5].
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Linkage analyses showed several regions on chromosomes
which may be related to PD (1q 2q (14), (15), 4q31-q34 (16,
17), 7 p (18, 19), 9q (17, 20), (21) 12q, 13q (17, 22), 14q (17,
23), 15q (15), and 22q (17, 24). Association studies on candi-
date genes that may be associated with PD investigate, among
others, COMT genes, 2 TPH, MAOA, 5-HT, 5-HTT [6–13].
Reports on the importance of regenerative processes in the
etiology of anxiety disorders are extremely scarce, and it is
worth pointing out that increased levels of stem cells are found
in the peripheral blood in different models of major illnesses
or deficits related to a significant level of stress (myocardial
infarction, burns, inflammatory bowel disease, stroke).
Therefore, their level in the peripheral blood can have poten-
tially diagnostic and predictive value in any of the disorders in
which there appears an increased stress level [14–18].
Animal models of stress provide information on the reduc-
tion of endogenous neurogenesis in the dentate gyrus [19]. It
is postulated that the process of neurogenesis is involved in
the pathogenesis of depression [20].
In the study byReif et al., it has been shown that weakening
of the neurogenesis process may play a role in schizophrenia,
but it does not seem to be important in affective disorders [21].
Kucharska et al. investigated the relationship between the first
episode of psychosis and HSC and VSEL levels. They
showed that in a group of people experiencing their first psy-
chotic episode in comparison with the control group, the
VSEL level is significantly higher [22]. The use of psychiatric
drugs has an effect on the process of neurogenesis. It has been
shown, for example, that the administration of fluoxetine in
adult rats increases the proliferation of new neurons and re-
duces the impact of stress on cell proliferation [23, 24].
Kigawa et al. indicated a higher effectiveness of neural stem
cell therapy, as well as sertraline and neural stem cell therapy
in the treatment of drug-resistant depression in animal models,
compared with animals treated only with sertraline [25].
In our research we investigated the behavior of HSCs
(hematopoetic stem cells) and VSELs (very small
embryonic-like stem cells). HSCs are stem cells, isolated from
the bone marrow or peripheral blood (1/10,000), which may
give rise to 8–10 lines of blood cells. At the turn of the II-
III trimester of pregnancy they colonize the bone marrow,
thanks to the SDF-1 (stromal derived factor-1) produced
by stromal cells and osteoblasts, which is a factor that
plays a role in their retention in the bone marrow [26,
27]. Their mobilization from the bone marrow happens
with the participation of G-CSF (granulocyte colony-
stimulating factor). The cells isolated from the bone mar-
row have the phenotype CD 34 +/CD38- [28].
VSELs are pluripotent stem cells with the phenotype of
CXCR4 +, AC133 +, CD34 +, SSEA-1 + (mouse), SSEA-
4 + (human), AP +, c-Met+, LIF-R +, CD45-, Lin-, HLA-
DR-,MHC I −, CD90-, CD29-, CD105-, we isolate them from
the bone marrow, umbilical cord blood and peripheral blood
[26]. They are found in the bone marrow, as a result of migra-
tion in the early stages of the ontogenetic development, and
are deposited in the mature bodies, including the brain
[29–32]. VSELs found in the peripheral blood could po-
tentially serve as a repair system in case of damage, in-
cluding damage to the CNS. It has been shown that they
are mobilized to peripheral blood in a mouse model of
stroke but also in the early phase of ischemic stroke in
humans [16, 33]. There is also some hope to apply them
in the repair processes of the retina [34].
In the body, stem cells are deposited in areas called niches,
they move thanks to a variety of factors which include the
components of the complement cascade, bioactive
chemokines and lysophospholipids [16, 35, 36]. An important
role in the regulation of those processes play: SDF-1 (stromal
derived factor), S1P (sphingosine-1-phosphate) and compo-
nents of the complement cascade. The interaction between
SDF-1 and CXCR4 receptor is responsible for the mainte-
nance of stem cell in the niches. Apart from the bone marrow,
such niches are found for example in the brain in the
periventricular zone of the lateral ventricles and the olfactory
bulb, as well as the subgranular zone of the hippocampus
dentate gyrus [37–39]. SDF-1 is involved in the development
of the CNS, as well as in the ongoing processes of
neuromodulation, neurogenesis and neuroprotection [40].
Receptors for S1P are present on oligodendrocytes, neurons
and nerve progenitor cells [41–43]. It takes part in
neurogenesis, plays an important role in directing stem cells
to the nerve tissue, stimulates the migration of progenitor cells
to damaged areas in the spinal cord [44], and affects the
growth and differentiation of oligodendrocytes [43].
Administration of migration inhibitors, the mediator of which
is S1P is used in multiple sclerosis therapy [45].
Anaphylatoxins C3a, C5a and C5b-9 have a signifi-
cant impact on the neuroglia and CNS neurons [46]. C3a
component affects the colonization of the bone marrow
niches by stem cells, stimulates chemotaxis as well as
hematopoietic and progenitor cell retention in the bone
marrow [47–49]. Lack of the final activation of the com-
plement cascade in mice results in a significant defect
within mobilization of HSCs [50]. Microglia is a media-
tor in the synthesis of C3 and C5 in the brain and the
emergence of C3a and C5a that are vasoactive and che-
motactic agents for neutrophils [51], while C5a has a
neuroprotective effect on mature cells [52]. On the
CNS neurons there are receptors for C5a, which respond
to stimulation by C5a in a stressful situation in the form
of ischemia [53]. Based on the above information and
the fact that reports on the role of stem cells in mental
disorders are sparse, we decided to see if the stress pres-
ent in panic disorder significantly affects the mobiliza-
tion of stem cells and the plasma concentration of factors
responsible for their movement.
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Material and Methods
Patient Group and Control Group
The study was approved by the Ethical Commission of the
PomeranianMedical University. All the individuals participat-
ing in the study provided their written consent. The investi-
gated group consisted of 30 patients, 12 of whom were diag-
nosed with panic disorder with agoraphobia and the remaining
18with panic disorder without agoraphobia according to ICD-
10. The participants did not suffer from other concurrent dis-
eases or mental disorders. The patients were compared to an
ethnically, BMI and gender-matched control group of 30
healthy volunteers without any diet restrictions or psychiatric
disorders, which were excluded through an examination by a
specialist psychiatrist. As is well known, the occurrence of
psychological disorders can be affected by events such as
complications related to pregnancy or childbirth, or certain
family issues so the groups were matched in this respect too
(Table 1). All persons with a history of serious medical
events during their lifetime (including glucose intoler-
ance), organic brain injuries or drug/alcohol dependence
were excluded from the study.
The diagnosis of PD was conducted by means of a psychi-
atric examination, MINI [54] and according to ICD-10
criteria. Demographic data, family history and history of
symptoms were assessed by a structured interview; we col-
lected information from the patients and their family. In order
to assess the severity of the anxiety disorder we applied the
HAM-A [55], to evaluate depressive disorders we used the
MADRS [56] (Table 2).
Research Procedures
Venous blood samples were collected in the morning,
on an empty stomach. We collected blood twice in the
patient group, the first time before they received medi-
cation, the second time after observed clinical improve-
ment, defined as withdrawal of panic attacks and after
the improvement in clinical scales (Hamilton, MADRS)
to a normal level. Psychiatric assessment, psychometric
evaluation, physical examination, and laboratory tests
were performed on the same day. Pharmacological treat-
ment was administered in accordance with Polish stan-
dards of treatment of anxiety disorders.
Flow Cytometric Analysis
Peripheral blood (PB) samples were lysed twice using BD
Pharm Lyse lysing buffer (BD Bioscience) at room tempera-
ture for 10 min and subsequently washed in phosphate-
buffered saline (PBS) with 2 % fetal bovine serum (FBS;
Sigma) to yield total nucleated cells (TNCs). TNCs were
stained for hematopoietic lineage markers using the following
fluorescein isothiocyanate (FITC)-conjugated antibodies
(Abs) against human proteins: CD2 (clone RPA-2.10); CD3
(clone UCHT1); CD14 (clone M5E2); CD16 (clone 3G8);
CD19 (clone HIB19); CD24 (clone ML5); CD56 (clone
Table 1 Study groups: demographics and clinical features
PG (n = 30) CG (n = 30) P
Mean age (years) 39,73 ± 9,4 34,13 ± 11.78 0,053
Gender Male - 7 (23,3 %) Male - 10 (33,33 %) 0,284
Female – 23 (76,67 %) Female - 20 (66,67 %)
Education Elementary – 0(0 %) Elementary – 1 (3,33 %) 0,24
Vocational school – 5 (17,86 %) Vocational school – 1 (3,33 %)
Secondary −10 (35,71 %) Secondary −13 (43,33 %)
Higher – 13 (46,43 %) Higher – 15 (50,0 %)
Pregnancy – any complications Yes – 6 (20 %) Yes – 3 (10 %) 0,27
No – 24 (80 %) No – 27 (90 %)
Natural childbirth Yes – 26 (86,67 %) Yes – 27 (90 %) 0,68
No – 4 (13.33 %) No – 3 (10 %)
Divorce of parents Yes – 8(26,67 %) Yes – 3 (10 %) 0,09
No – 22 (73,33 %) No - 27 (90 %)
Family history of psychotic disorders Yes – 3 (10 %) Yes – 6 (20 %) 0,27
No – 27 (90 %) No – 24(80 %)
Smoking subjects Yes – 15(55,56 %) Yes – 11 (36,67 %) 0,15
No – 12 (44,44 %) No – 19 (63,33 %)
BMI 24,75 ± 4,8 24.61 ± 4.33 0,90
Mean duration of anxiety (days) 1564 ± 2297 -
Mean duration of treatment(days) 24,47 ± 16,26
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NCAM16.2); CD66b (clone G10F5); and CD235a (clone
GA-R2) (all from BD Bioscience). The cells were simulta-
neously stained for the panleukocytic marker, CD45 phycoer-
ythrin (PE)-conjugated Abs, (clone HI30; BD Biosciences)
and one of the following antigens CD 34-allophycocyanin
(APC)-conjugated Abs, (clone 581; BD Bioscience) or
CD133 (CD133/1, APC-conjugated Abs; Miltenyi Biotec).
Additionally following FITC-conjugated isotype controls:
Mouse IgG1, (clone MOPC-21), Mouse IgG2a, (clone
G155–178), Mouse IgG2b, (clone 27–35), PE-conjugated
isotype control Mouse IgG1, (clone MOPC-21) and APC-
conjugated isotype control Mouse IgG1, (clone MOPC-21)
(all from BD Bioscience) were used. In addition, APC-
conjugated isotype control Mouse IgG1 (clone IS5-21F5;
Miltenyi Biotec) were used. Staining was performed in
PBS with 2 % FBS on ice for 30 min. Cells were subse-
quently washed, resuspended, and analyzed using an
NAVIOS Flow Cytometer (Beckman Coulter). At least
106 events were acquired from each sample. The absolute
numbers of VSEL and the absolute number of white blood
cells were calculated (individually for each patient) per
1 ml PB based on the percent content of these cells as
detected by flow cytometry. Kaluza software (Beckman
Coulter) was used for analysis [16, 57].
Determination of S1P by Reversed-Phase
High-Performance Liquid Chromatography
Fresh blood samples were centrifuged (250 g; 10min., 20 °C),
and the plasma was frozen at −80 °C for further study. Plasma
was defrosted at room temperature, the internal standard (D-
erythro-sphingosine-1-phosphate, S1P C17, Avanti Polar
Lipids), 1 M NaCl, methanol and 37 % HCl was added, and
the samples were vortexed. Chloroform (2ml) was added, and
the samples were mixed in a test tube rotator. Samples were
centrifuged, and the lower chloroform phase was transferred
into a new tube. Following a re-extraction with another 2 ml of
chloroform, the chloroform phases were combined and
vacuum-dried in a SpeedVac for 45 min at 45 °C. The residue
that remained after evaporation was reconstituted in methanol,
incubated with OPA (o-phthaldialdehyde), methanol,
mercaptoethanol and boric acid (pH 10,5) and centrifuged.
The supernatant was analyzed using a Hewlett Packard
Series 1200 chromatograph. Chromatographic data were
processed by HP Chemstation software (Hewlett Packard,
now Agilent). Reversed-phase HPLC was performed on a
Cosmosil C18-ARII column (250 mm × 4 mm, 5 μm)
(Phenomenex) with a C18-ARII cartridge (10 mm × 4,6 mm)
packed with the same material. The column temperature was
25°C. An isocratic method was used where the mobile phase
was composed by mixing K2HPO4 (pH 5,5) and methanol
(15:85; v/v). The flow rate was 1 ml/min, and 50 μl samples
were injected every 30 min. Detection was performed with a
fluorescence detector at 340 nm excitation and 455 nm emis-
sion wavelengths. The quantification was based on peak areas
with internal standard calibration [58–60].
Real-Time Quantitative Reverse Transcription PCR
(qRT-PCR)
Total RNAwas isolated from lysed blood with the RNeasy Kit
(Qiagen). The RNAwas reverse transcribed with FirstStrand
cDNA synthesis kit and oligo-dT primers (Fermentas).
Quantitative assessment of mRNA levels was performed by
real-time RT-PCR on an ABI 7500Fast instrument with Power
SYBR Green PCR Master Mix reagent. Real-time conditions
were as follows: 95 °C (15 s), 40 cycles at 95 °C (15 s), and
60 °C (1 min). According to melting point analysis, only one
PCR product was amplified under these conditions. The rela-
tive quantity of a target, normalized to the endogenous control
β-2 microglobulin gene and relative to a calibrator, is
expressed as 2-ΔΔCt (−fold difference), where Ct is the
threshold cycle, ΔCt = (Ct of target genes) – (Ct of en-
dogenous control gene, β-2 microglobulin), and
ΔΔCt = (ΔCt of samples for target gene) – (ΔCt of cali-
brator for the target gene) [16, 61].
Determination of C5b-9, C3a And C5a Complement
Components and SDF-1
C5b-9 (MAC), C3a and C5a complement components were
determined by using the Human C5b-9 ELISA Kit, Human
C3a ELISA Kit and Human C5a ELISA Kit (BD OptEIA),
respectively.
SDF-1 was determined using a Human CXCL12/SDF-1
ELISA Kit (R&D Systems) [58, 62–64].
Statistical Analysis
Distribution of continuous variables was examined with the
Shapiro-Wilk test. Comparison of quantitative variables was
performed with the Mann-Whitney-U test. Relative continu-
ous variables were compared with the Wilcoxon test.
Dichotomous variables comparison was performed with the
Table 2 Mean MADRS and
HAM-A scores in patient group
before and after treatment
Mean score before treatment Mean score after treatment p
HAM-A 22,2 ± 9,08 4,03 ± 5,57 0,00001
MADRS 8867 ± 5,82 1,9 ± 4413 0,00004
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use of the exact Fisher test. As the measure of statistical sig-
nificance we used p < 0.05. All statistical analyses were per-
formed using Statistica 10, by StatSoft, 2013.
Discussion
In the course of our research, we looked for the answer to the
question of whether anxiety disorders affect the mobilization
of stem cells into the peripheral blood, and hence, whether
stem cell concentration and associated humoral factors can
become a new diagnostic tool for anxiety disorders. Our study
showed a statistically significant decrease in the level of he-
matopoietic stem cells HSCs (Lin−/CD45 +/AC133 +) in the
patient group as compared to the control group both before
and after treatment (Table 3). Available publications do not
include analyses concerning panic disorder and the related
behavior of stem cells. Therefore, we investigated the impact
of stress on stem cells. Wohleb et al. demonstrated that mice
subjected to the influence of repeated stress exhibit anxiety
disorder type behaviors associated with an increase in the
number of monocytes, cytokines and chemokines involved
in the recruitment of myeloid cells as well as an increase in
the number of monocytes in particular brain structures. In
contrast, mice with chemokine receptor 2 (CCR2) knockout
or fractalkine receptor (CX3CR1) knockout do not exhibit
such behavior and are not able to recruit macrophages to the
brain [65].
In the study by Heidt et al. it has been shown that chronic
stress increases the level of monocytes and neutrophils in
humans, whereas the search for the source of leukocytosis in
mice suggested that stress activates upstream hematopoietic
stem cells [66]. Riddell et al. demonstrated that acute psycho-
logical stress in humans affects mobilisation of HSC cells and
EPCs (endothelial PCs), as well as an increase in the number
of monocytes and lymphocytes, but they did not observe an
increase in circulating stem cells after administration of B-
agonist receptor [67]. The participants of our study
experienced chronic stress (duration of 1564 ± 2297 days),
which was probably the cause of the observed differences
between our results and those obtained by Riddell et al.
In the study by Kucharska-Mazur et al., they looked at
selected sub-populations of stem cells and factors responsible
for their movements in patients with their first psychotic epi-
sode. They observed an increase in the number of VSELs CD
34 + compared with the control group. Applied treatment did
not result in a reduction in the number of these stem cells.
Established deviations can be potentially treated as an indica-
tor of a disturbance within the development process of the
brain, which remains in line with Weinberger’s theory of
schizophrenia as a neurodevelopmental disorder [22].
In the course of their research, Ferensztajn-Rochowiak
et al. looked at the behavior of stem cells in patients with
bipolar disorder. In the group of patients who did not receive
lithium, the levels of VSELs CD 34 + were significantly
higher compared to the control group, and they correlatedwith
the duration of the disease [68, 69]. If we compare the results
obtained in patients with panic disorder, then the study of stem
cells allows to differentiate qualitatively between psychotic
and anxiety disorders.
Next, we dealt with the influence of pharmacotherapy on the
number of stem cells.We only observed that the level of VSELs
(Lin−/CD45−/CD133 +) was significantly lower in the patient
group before treatment as compared to after treatment, which
may indicate the role of the administered pharmacotherapy
(Table 4); from literature data we know that e.g. antidepressant
treatment causes increased neurogenesis [23, 24].
Factors responsible for the movement of stem cells in the
body are, among others, complement proteins, chemokines
and lysophospholipids. In our analysis we demonstrated sig-
nificantly lower levels of C3a, C5a, C5b, S1P and SDF-1 in
PG compared to CG both before and after treatment (Table 3),
we did not, however, manage to show any statistically
significant differences when comparing the patient group
before and after treatment (Table 4). As a potential cause
of reduced concentrations of these substances we could
Table 3 Comparison of stem cells concentrations and factors responsible for their movement in PG BT vs CG and comparison of the mean number of
stem cells and factors responsible for their movement in PG AT vs CG.
PG BT (n = 30) CG (n = 30) P PG AT (n = 30) CG (n = 30) P
VSELs (Lin−/CD45−/CD34+) [No.of cells/μl] 0,155 ± 0,079 0,160 ± 0,103 0,82 0,158 ± 0,064 0,160 ± 0,103 0,93
VSELs (Lin−/CD45−/CD133+) [No. of cells/μl] 0,102 ± 0,048 0,116 ± 0,073 0,38 0,134 ± 0,074 0,116 ± 0,073 0,34
HSCs (Lin−/CD45+/CD34+) [No. of cells/μl] 1173 ± 0,522 1234 ± 0,692 0,7 1265 ± 0,62 1234 ± 0,692 0,85
HSCs (Lin−/CD45+/AC133+) [No.of cells/μl] 0,860 ± 0,43 1229 ± 0,736 0,02 0,897 ± 0,45 1229 ± 0,736 0,04
C3a [ng/ml] 469,56 ± 116,6 586,67 ± 136,2 0,00071 449,9 ± 86,13 586,67 ± 136,2 0,00002
C5a [ng/ml] 27 ± 13 54,11 ± 28,9 0,00001 26,98 ± 12,67 54,11 ± 28,9 0,00001
C5b-9 [ng/ml] 73,97 ± 77,29 235,95 ± 317,5 0,0087 61,43 ± 39,76 235,95 ± 317,5 0,0041
SDF-1 [pg/ml] 2101 ± 401 2828 ± 395 0,00001 2057,4 ± 422 2828 ± 395 0,00001
S1P [μg/ml] 2,05 ± 0,38 2,48 ± 0,13 0,00001 2,00 ± 0,32 2,48 ± 0,13 0,00001
Stem Cell Rev and Rep (2017) 13:217–225 221
suggest the impact of chronic stress. In the available lit-
erature we did not find information on the determination
of the aforementioned factors in anxiety disorders, and
therefore we decided to analyze the results with relation
to data from the literature on psychoses.
In their study on patients with psychosis, Kucharska et al.
showed significantly lower concentrations of S1P in the pa-
tient group before and after treatment as compared with the
control group, and reduced levels of C3a in the patient group
before treatment as compared with the control group, which
increased after treatment. They did not, however, demonstrate
changes in the concentrations of the other investigated factors.
The results may also be used in differentiating between psy-
choses and anxiety disorders [22].
In her study on the complement components in psychoses, on
the basis of available literature, Mayilyan pointed out varied re-
search results, which could be accounted for by the use of clini-
cally different patient groups [70]. In a study comparing the con-
centrations of C3 in paranoid schizophrenia (MB), bipolar dis-
ease in euthymia (BD) and in healthy individuals, Santos Soria
et al. demonstrated a significantly higher level of C3 in patients
with schizophrenia as compared with the control group and the
patients with BD in euthymia. C3 levels did not differ significant-
ly in control group compared to BP patients in euthymia [71].
This work is the first attempt to analyze the mobilization of
stem cells in panic disorder. Our results are a contribution to
the further analysis of the role of regeneration system in anx-
iety disorders. The limitation of this study is a relatively small
number of participants, which delivered interesting prelimi-
nary findings but definitively requires replication studies.
Based on our Analyses weHave Formulated the Following
Conclusions
1. Long-term panic disorder reduces the mobilization of
HSCs (Lin−/CD45 +/AC133 +) from the bone marrow
to the peripheral blood and a short-term use of antidepres-
sants does not increase this mobilization.
2. The number of VSELs does not constitute a differentiat-
ing factor between the patient and control group, but the
use of antidepressants causes an increase in the mobiliza-
tion of VSELs (Lin−/CD45−/CD133 +) to the peripheral
blood.
3. In patients with panic disorder we have observed a signif-
icantly lower concentration of the investigated factors re-
sponsible for stem cell movement, and administered phar-
macotherapy has not resulted in substantial changes to
that concentration.
4. The study of stem cells and factors associated with their
movement might be helpful in the diagnostics of panic dis-
order, as well as its differentiation from psychotic disorders
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